Company Profile
Bio-Reference Laboratories Stock Price, News & Analysis
- Ticker:
- BRLI
- Exchange:
- NASDAQ
- Sector:
- MedTech
- Location:
- United States and has operated as a healthcare diagnostics business
Why the stock is moving
Current closing-price context is not available for BRLI.
Company overview
Diversified Healthcare and Diagnostics Platform
The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs. BioReference-related diagnostics, commercial products, and the ModeX platform form its principal value drivers.
Diagnostics Business
The diagnostics business includes core laboratory services and specialty tests such as the 4Kscore Test. BioReference provides an established clinical testing infrastructure alongside OPKO’s therapeutic activities.
Commercial Medicines and Partner Economics
The pharmaceutical portfolio includes Rayaldee, profit-sharing economics from NGENLA, and products sold in international markets. Partnerships with companies including Lilly, Regeneron, and Nicoya add research funding, commercial opportunities, and potential milestone or royalty economics.
ModeX Multispecific Antibody Platform
ModeX is a central source of pipeline innovation. Programs include antibody-targeted lipid nanoparticles for in vivo CAR T-cell generation, the MDX2003 tetraspecific T-cell engager-expander, and several Phase 1 assets focused on multispecific antibodies and immune-cell modulation.
Future catalysts
ModeX plans to initiate a company-sponsored Phase 1 study of its in vivo CAR T program in autoimmune disease in late 2026 or early 2027.
Enrollment in the MDX2301 Phase 1 study is expected to be completed in the third quarter of 2026, with initial data anticipated in late 2026 or early 2027.
Recent news
- 01
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
Source: Bio-Reference Laboratories
- 02
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
Source: Bio-Reference Laboratories
- 03
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
Source: Bio-Reference Laboratories
- 04
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
Source: Bio-Reference Laboratories
- 05
OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results
Source: Bio-Reference Laboratories
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Bio-Reference Laboratories do?
Diversified Healthcare and Diagnostics Platform The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs. BioReference-related diagnostics, commercial products, and the ModeX platform form its principal...
On which exchange is BRLI stock listed?
Bio-Reference Laboratories (BRLI) is associated with NASDAQ, United States and has operated as a healthcare diagnostics business, MedTech.
What is Diversified?
Diversified Healthcare and Diagnostics Platform The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs.
Which conditions is Bio-Reference Laboratories targeting with Diversified?
Diversified Healthcare and Diagnostics Platform The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs. BioReference-related diagnostics, commercial products, and the ModeX platform form its principal...
How does Bio-Reference Laboratories describe recent progress with Diversified?
ModeX plans to initiate a company-sponsored Phase 1 study of its in vivo CAR T program in autoimmune disease in late 2026 or early 2027. Enrollment in the MDX2301 Phase 1 study is expected to be completed in the third quarter of 2026, with initial data anticipated in late 2026 or early 2027.
What is Healthcare?
Diversified Healthcare and Diagnostics Platform The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs.
What should investors watch for with Healthcare?
ModeX plans to initiate a company-sponsored Phase 1 study of its in vivo CAR T program in autoimmune disease in late 2026 or early 2027. Enrollment in the MDX2301 Phase 1 study is expected to be completed in the third quarter of 2026, with initial data anticipated in late 2026 or early 2027.
What is Diagnostics?
Diversified Healthcare and Diagnostics Platform The source release primarily describes OPKO Health, a multinational biopharmaceutical and diagnostics company with laboratory services, specialty testing, commercial medicines, and multiple clinical-stage programs.